Exploring (1) cognitive functioning in WHO grade I meningioma patients, and (2) the relation between cognitive functioning and functional connectivity in this patient group.
ID
Source
Brief title
Condition
- Nervous system neoplasms malignant and unspecified NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Main study parameters are cognitive functioning (measured by an extensive
neuropsychological test battery) and MEG-measures of functional connectivity
(synchronization likelihood).
Secondary outcome
n.v.t.
Background summary
Patients with meningiomas often suffer from cognitive disturbances, but
relatively few studies have been published on this subject. Disturbances in
executive functioning seem to predominate in these patients, but memory,
language, concentration and orientation impairments have also been reported.
The precise pattern of cognitive deficits in meningioma patients remains to be
further investigated.
Evidence has accumulated that higher cognitive functions require functional
interactions, or connectivity, between multiple distinct neural brain networks.
Functional connectivity * as this notion is termed * thus relies not only on
anatomical, but also on functional interactions between several brain regions.
Magnetoencephalography (MEG) is an excellent way to capture the dynamics of the
electromagnetic fields of the brain, which can help us understand how
functional connectivity relates to cognitive functioning in several patient
groups.
Functional connectivity has been proven to differ in brain tumor patients,
relative to healthy controls. Moreover, we recently found low-grade glioma
patients to have altered levels of functional connectivity, which were
correlated with disturbed cognitive functioning. The relation between
functional connectivity and cognitive functioning in meningioma patients has
not been investigated yet.
Study objective
Exploring (1) cognitive functioning in WHO grade I meningioma patients, and (2)
the relation between cognitive functioning and functional connectivity in this
patient group.
Study design
Multi-centre cross-sectional study.
Study burden and risks
The burden associated with participation for patients consists of (1) a visit
to the outpatients* clinic, (2) administration of a neuropsychological test
battery, which will be administered in the patients* home, and (3) examination
through magnetoencephalography (MEG). No health-related risks are involved in
this study. In our view, the burden for meningioma patients associated with
participation is proportionate to the potential value of this research.
Van der Boechorststraat 7
1081 BT Amsterdam
Nederland
Van der Boechorststraat 7
1081 BT Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
(1) Adult (> 18 years), (2) histologically proven meningioma WHO grade I, (3) no clinical or radiological signs of tumor progression for at least one year prior to inclusion date, (4) end of treatment at least one year prior to inclusion, and (5) written informed consent.
Exclusion criteria
(1) Use of centrally acting drugs, including corticosteroids, other than antiepileptic drugs, (2) a medical condition that interferes with normal cognitive functioning, (3) cerebrovascular pathology, (4) congenital CNS malformations, (5) multiple sclerosis, (6) Parkinson*s disease, (7) psychiatric disease or symptoms, (8) optic nerve meningiomas, (9) insufficient mastery of the Dutch language, and (10) inability to communicate adequately.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL18603.029.07 |